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Introduction
The transcriptional corepressors C-terminal binding protein 
(CtBP) 1 and 2 repress gene expression by interacting with DNA 
binding transcription factors and recruiting histone methyl-
transferases, histone deacetylases, polycomb group proteins 
and other chromatin remodeling proteins to targeted promot-
ers.1-6 CtBP repression targets include epithelial and proapop-
totic genes, consistent with its known roles in promoting cell 
survival and migration.7,8 Transcriptional repression requires 
CtBP’s dehydrogenase/NADH binding domain and increases in 
intracellular NADH promote CtBP oligomerization and tran-
scriptional repressor activity.9-14 Hypoxia and extracellular glu-
cose levels, both stimuli affecting NADH levels, also modulate 
CtBP’s effects on cell survival and migration.7,15 These findings 
have established CtBP as a redox sensor that regulates transcrip-
tion based on the cell’s metabolic environment.
A growing body of evidence suggests CtBP plays a role 
in human cancer.16 CtBP promotes multiple pro-oncogenic 
the CtBp transcriptional corepressors promote cancer cell survival and migration/invasion. CtBp senses cellular 
metabolism via a regulatory dehydrogenase domain, and is antagonized by p14/p19ARF tumor suppressors. the CtBp 
dehydrogenase substrate 4-methylthio-2-oxobutyric acid (MtoB) can act as a CtBp inhibitor at high concentrations, and 
is cytotoxic to cancer cells. MtoB induced apoptosis was p53-independent, correlated with the derepression of the pro-
apoptotic CtBp repression target Bik, and was rescued by CtBp overexpression or Bik silencing. MtoB did not induce 
apoptosis in mouse embryonic fibroblasts (MeFs), but was increasingly cytotoxic to immortalized and transformed MeFs, 
suggesting that CtBp inhibition may provide a suitable therapeutic index for cancer therapy. In human colon cancer 
cell peritoneal xenografts, MtoB treatment decreased tumor burden and induced tumor cell apoptosis. to verify the 
potential utility of CtBp as a therapeutic target in human cancer, the expression of CtBp and its negative regulator ARF 
was studied in a series of resected human colon adenocarcinomas. CtBp and ARF levels were inversely-correlated, with 
elevated CtBp levels (compared with adjacent normal tissue) observed in greater than 60% of specimens, with ARF absent 
in nearly all specimens exhibiting elevated CtBp levels. targeting CtBp may represent a useful therapeutic strategy in 
human malignancies.
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activities, including EMT,8 cell migration/invasion,7,17,18 and cell 
survival8,19 through repression of epithelial genes such as kera-
tin-8 and E-cadherin and apoptosis genes such as Bik, Noxa, 
Puma and PERP.8,20 Additionally, CtBP targets multiple growth 
inhibitory tumor suppressors for repression, including PTEN, 
p16INK4a and p15INK4b.8,18,21,22
In addition to opposing the activities of multiple tumor sup-
pressors, CtBP is also the target of inhibition by multiple tumor 
suppressors. In response to UV radiation, CtBP is phosophory-
lated by HIPK2 and targeted for ubiquitination and proteasomal- 
mediated degradation,23 resulting in apoptosis. The adenomatous 
polyposis coli tumor suppressor (APC) targets CtBP for degrada-
tion, and inactivation of this APC activity may be a necessary step 
in colonic adenoma formation.24,25 Finally, the tumor suppressor 
ARF can also downregulate CtBP by targeting it for proteasomal 
degradation, inducing Bik-dependent apoptosis.19,26 ARF is also 
capable of blocking CtBP-mediated repression of PTEN and by 
doing so, ARF can inhibit CtBP-dependent hypoxia-induced, 
cancer cell migration.18
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no statistically significant difference in the effects of MTOB 
between HCT116+/+ and HCT116-/- cell lines, indicating that the 
loss of viability in these cells was p53-independent. Other cancer 
cell lines derived from pancreas, bone and colon were also tested, 
all showing varying degrees of sensitivity to MTOB’s cytotoxic 
effects (Suppl. Fig. 1A).
Consistent with previous reports, cytotoxic MTOB concen-
trations were in the mM range in this 72 hr viability assay.29 To 
determine if lower concentrations of MTOB might be effective 
over a longer-term assay period, a 7-day colony survival assay was 
performed using HCT116-/- cells. Cells were treated for 72 hours 
with MTOB and then replaced with fresh compound-free media 
for 96 hours prior to counting (Fig. 1B). At seven days, the IC
50
 
for MTOB was approximately 200 μM and 1 mM MTOB was 
91% lethal, demonstrating significantly more potency for MTOB 
than seen at 72 hours and with a cellular IC
50
 closer to the IC
50
 
for in vitro CtBP inhibition by MTOB.27 Similar results were 
obtained using HCT116+/+ cells (data not shown).
In order to compare the efficacy of MTOB to other known 
cytotoxic agents, HCT116-/- or +/+ cells were treated with 1, 10 or 
25 μM cisplatin in the presence or absence of 4 mM MTOB for 
48 hours (Fig. 1C) and cell viability determined. Treatment with 
cisplatin resulted in a dose-dependent loss of viability in both cell 
lines, with the p53-null cells showing greater sensitivity at higher 
concentrations (Fig. 1C). In the presence of 4 mM MTOB and 
1 μM cisplatin, cell viability dropped from 76% to 41% in the 
HCT116-/- cells and from 79% to 52% in the HCT116+/+ cells, 
suggesting an additive effect (Fig. 1C). At higher cisplatin doses, 
the difference between control and MTOB-treated cells disap-
peared in the p53-null cells, but was enhanced in the p53 wild-
type setting, with the cytotoxicity of 25 μM cisplatin at 48 hours 
increasing from 46% viability to only 4% viability in the pres-
ence of MTOB (Fig. 1C), suggesting synergy. MTOB was also 
compared to and combined with, 5-fluorouracil and doxorubicin, 
but no synergy was observed between MTOB and these agents in 
HCT116-/- and +/+ cells (Suppl. Fig. 1B).
MTOB displaces CtBP from the Bik promoter and induces 
Bik expression and apoptosis. CtBP transcriptional repres-
sion is dependent on active regulation by the dehydrogenase 
domain.11,13,14 MTOB at high concentrations may inhibit the 
dehydrogenase, impacting repression function.27 Reduction of 
CtBP2 levels by RNAi has been previously shown to decrease its 
recruitment to BKLF binding sites in the promoter of the BH3 
gene Bik, causing Bik upregulation and apoptosis in HCT116-/- 
cells.26 In order to determine if MTOB had a similar effect on 
promoter recruitment of the CtBP co-repressor complex, the Bik 
promoter was analyzed by CtBP chromatin immunoprecipitation 
(ChIP) in the presence and absence of MTOB. HCT116-/- cells 
were treated with 4 mM MTOB or NaCl for 18 hours and the 
chromatin fraction harvested, immunoprecipitated with IgG, 
anti-CtBP1 or anti-CtBP2 antibodies and the ChIPs analyzed 
for bound Bik promoter fragment (Fig. 2A).26 Negative control 
PCR primers (NS) that amplify a fragment 10 kb upstream from 
the Bik promoter were used to establish specificity (Fig. 2A). 
PCR amplification of input chromatin with Bik and NS prim-
ers showed equal amounts of amplification in both treated and 
While the physiologic substrate for CtBP’s dehydrogenase 
activity has not been definitively identified, the penultimate 
compound in the methionine salvage pathway, 2-keto-4-methyl-
thiobutyrate (referred to hereafter as: 4-methylthio-2-oxobutyric 
acid; MTOB), is a specific and 80 to 5,000-fold better sub-
strate for CtBP’s dehydrogenase then other structurally similar 
α-ketoacids.27 The catalysis of MTOB shows bi-phasic kinetics, 
with higher concentrations of MTOB inhibiting the reaction.27
MTOB exhibits significant cytotoxicity against cancer cell 
lines and is also an inhibitor of ornithine decarboxylase (ODC), 
which links the methionine biosynthesis and polyamine path-
ways.28 ODC inhibition is likely not responsible for MTOB’s 
cytotoxicity in cancer cell lines, since supplementation with 
polyamines to bypass ODC inhibition did not reverse MTOB 
induced cell death.28 MTOB is also a poor substrate for lactate 
dehydrogenase, suggesting that manipulation of MTOB levels 
should not perturb the cellular NAD+/NADH ratio in the way 
that manipulating pyruvate levels can, leaving the true cellular 
mechanism for MTOB toxicity unknown.29
Based on its oncogenic properties and intrinsic enzymatic 
activity, CtBP represents a potential therapeutic target in neo-
plastic disease. The extent and mechanism of the CtBP sub-
strate MTOB’s cytotoxicity was therefore studied in vitro and 
in vivo. Treatment with MTOB induced p53-independent apop-
tosis in a variety of human cancer cell lines. MTOB displaced 
CtBP from the promoter of the pro-apoptotic gene Bik, increas-
ing Bik expression in a dose-dependent manner. Overexpression 
of CtBP2 or RNAi mediated silencing of Bik, rescued MTOB 
toxicity. MTOB was demonstrated to be less toxic in primary 
and immortalized mouse embryonic fibroblasts (MEFs), than in 
those oncogenically transformed with c-Myc and mutant Ras. 
MTOB treatment also effectively induced apoptosis and reduced 
the tumor burden in human colon cancer cell peritoneal xeno-
grafts in nude mice. The expression of CtBP and its negative 
regulator ARF were examined in resected human colon adeno-
carcinomas and CtBP and ARF levels demonstrated a strong 
inverse correlation, with CtBP1/2 upregulated in greater than 
60% of tumors compared with matched adjacent normal tissue. 
CtBP may therefore represent a physiologically relevant therapeu-
tic target in human cancer.
Results
The CtBP substrate MTOB induces apoptosis in human 
colorectal cancer cell lines. CtBP transcription repressors repre-
sent potentially attractive cancer drug targets since they encode a 
potentially “druggable” dehydrogenase domain and their silenc-
ing by RNAi leads to anti-cancer effects, including apoptosis 
and abrogation of cancer cell migration/invasion.10,17-19 Based 
on the identification of MTOB as a CtBP substrate, as well as 
its reported cytotoxicity, the effect of MTOB on cell viability 
was determined in cell lines known to rely on CtBP for regula-
tion of survival [HCT116 colon carcinoma wild type (+/+) or 
null (-/-) for p53 (Fig. 1A)].19,29 After 72 hours of MTOB treat-
ment, a dose-dependent loss in cell viability was observed, with 
a near-complete lethal effect at 10 mM (Fig. 1A). There was 
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Having demonstrated that MTOB can displace CtBP1/2 
from the Bik and E-cadherin promoters, MTOB’s functional 
effect on CtBP repressor activity was investigated. HCT116-
/- cells were treated with 10 mM MTOB or 10 mM NaCl and 
mRNA analyzed by qPCR for Bik expression (Fig. 2B). The 
MTOB-treated cells showed a six-fold increase in relative Bik 
expression compared to vehicle treated cells (Fig. 2B). Bik pro-
tein levels were checked in HCT116-/- cells 24 hours after treat-
ment with vehicle, 1 mM or 4 mM MTOB (Fig. 2C, left parts) 
and Bik levels increased in a dose-dependent manner. Likewise, 
treatment of MCF7 cells with MTOB led to the upregulation of 
E-cadherin protein levels, demonstrating that MTOB’s ability to 
cause derepression of a CtBP target gene is neither gene- nor cell-
type-specific (Suppl. Fig. 2B).
untreated cells and there was little background binding of the 
Bik promoter in the IgG control ChIP (Fig. 2A). Bik promoter 
binding was nearly completely suppressed in the anti-CtBP2 chip 
from MTOB-treated cells, while the anti-CtBP2 ChIP from 
NaCl-treated cells demonstrated easily detectable CtBP2 inter-
action with the Bik promoter (Fig. 2A). The anti-CtBP1 ChIP 
showed slightly different results, with qualitatively less basal pro-
moter binding in the NaCl-treated sample, but a still detectable 
loss of Bik promoter binding after MTOB treatment, as seen with 
CtBP2 (Fig. 2A). Confirming these results with another CtBP 
repression target, MTOB treatment of MCF7 cells resulted in 
decreased CtBP binding to the E-cadherin promoter (Suppl. Fig. 
2A), demonstrating that MTOB treatment can cause the disso-
ciation of CtBP from multiple CtBP target promoters.
Figure 1. the CtBp substrate MtoB is cytotoxic to colon cancer cell lines. (A) the colon adenocarcinoma cell lines HCt116 wild type (+/+) or p53-null 
(-/-), were treated for 72 hours with MtoB or normal media (Control). Cell viability was determined by Mtt assay and normalized to the untreated 
samples. the average of three separate experiments is shown, and error bars equal the standard error of the mean (SeM). (B) HCt116-/- cells were plated 
at low density and treated with normal media or media containing the indicated amount of MtoB for 72 hours, and then replaced with compound-
free media for four days. Colony formation was assessed by GIeMSA staining, and all wells were normalized to the untreated control. experiments were 
done three times in duplicate, with a representative plate shown. error bars represent the SeM. (C) HCt116-/- and +/+ cells were treated with the indi-
cated concentrations of cisplatin in the presence or absence of 4 mM MtoB for 48 hours, and cell viability assessed by Mtt assay. error bars represent 
the SeM.
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In the control transfectants treated with 4 mM MTOB, there 
was an induction of Bik compared to the untreated cells, whereas 
the CtBP2-V5 cells showed no Bik induction upon MTOB 
treatment (Fig. 3B). Thus, rescue of MTOB-induced cell death 
by CtBP2 overexpression correlated with suppression of Bik 
induction.
To investigate whether MTOB-induced cell death was due in 
part or whole to reversal of CtBP repression of Bik, HCT116-/- 
cells stably expressing GFP shRNA or one of two different 
Bik shRNAs26 were treated with vehicle or 4 mM MTOB for 
72 hours and viability determined by trypan blue staining 
(Fig. 3C and D). ShGFP cells showed normal sensitivity to 
MTOB, with reduction in viability from 100 to 44% and an 
increase in dead cells from 7 to 39% (Fig. 3C, left and right 
parts). Both shBik1 and shBik2 showed a significant abil-
ity to rescue MTOB-induced cell death, with viability post-
MTOB increasing from 44% in shGFP cells to 73% and 94% 
in shBik1 (p = 0.001) and shBik2 (p = 0.002) cells, respec-
tively (Fig. 3C, left part). Cell death was also significantly 
reduced in shBik1 and 2 cells post-MTOB, with reductions 
in cell non-viability from 38% (shGFP cells) to 12% and 15% 
non-viability in shBik1 (p < 0.0001) and shBik2 (p = 0.0001) 
cells, respectively (Fig. 3C, right part). Knockdown efficiencies 
for the two hairpins were unequal (Fig. 3D) with shBik1 hav-
ing reduced knockdown (30%) compared to shBik2 (>90%), 
correlating with the more robust rescue of viability seen with 
shBik2 (Fig. 3C). Thus, inhibition of CtBP2 repression of Bik is 
largely responsible for MTOB-induced cytotoxicity in 
HCT116-/- cells.
Given the known repression of pro-apoptotic genes, includ-
ing Bik, by CtBP, the likely possibility that MTOB cytotoxicity 
was due to induction of apoptosis was investigated. Treatment 
of HCT116-/- cells with MTOB resulted in a dose-dependent 
increase in caspase activation, as measured by levels of cleaved 
caspase 3 (Fig. 2C, right parts). Similar caspase activation was 
induced in MTOB-treated MCF7 cells (Suppl. Fig. 2C). Thus, 
MTOB impacts on CtBP2 occupancy on target promoters and 
resultant changes in gene expression were found to correlate with 
activation of apoptotic pathways.
MTOB modulates the CtBP/Bik pathway to induce apop-
tosis. Having shown that MTOB treatment inhibits CtBP tran-
scriptional repression of a target gene product, the hypothesis 
that CtBP is a primary target for MTOB was tested by attempt-
ing to rescue MTOB cytotoxicity with CtBP overexpression. 
HCT116-/- cells were stably transfected with human V5-tagged 
CtBP2 cDNA (CtBP2-V5) or empty vector (pCDNA), treated 
with 4 mM MTOB or vehicle for 72 hours and then stained with 
trypan blue (Fig. 3A). Total cell viability was reduced by 66% in 
the control cells treated with 4 mM MTOB, while the CtBP2-V5 
cells treated with 4 mM MTOB showed no significant loss in cell 
viability (Fig. 3A, left part). These results were mirrored by the 
increase in the percentage of non-viable cells in the control trans-
fectants from 12 to 46% in the vehicle and 4 mM MTOB-treated 
cells, respectively, while the CtBP2-V5 cells showed no difference 
between the untreated and treated cells, with 13 and 12% non-
viable cells noted, respectively (Fig. 3A, right part). CtBP2-V5 
cells were thus completely resistant to MTOB-induced cell death. 
This resistance correlated well with Bik levels in the two cell lines. 
Figure 2. MtoB modulates CtBp transcriptional functions. (A) MtoB displaces CtBp2 from the Bik promoter. HCt116-/- cells were treated for 18 hours 
with 4 mM MtoB or NaCl (control), and CtBp2 and CtBp1 association with the Bik promoter assessed by ChIp using control IgG, anti-CtBp 1 or 2 
antibodies and formaldehyde crosslinked chromatin. DNA retained in the ChIps was analyzed by pCR using either Bik promoter primers that amplify a 
fragment containing BKLF sites (Bik) or a fragment of DNA located 10 kb upstream of the Bik transcription start site (NS). (B) MtoB increases expression 
of Bik mRNA. Quantitative real-time pCR using RNA prepared from HCt116 p53-/-cells treated with NaCl (control) or 10 mM MtoB. error bars are equal 
to the SeM. (C) MtoB regulates Bik expression. HCt116 p53-/- cells were treated with control media (-) or media containing 1 mM or 4 mM MtoB. Bik, 
cleaved caspase 3, and GApDH levels were determined by immunoblotting of cell lysates prepared 24 hr after treatment.
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rendered cells substantially more vulnerable to MTOB treat-
ment, with 4 mM MTOB reducing survival by 98% after 7 days 
(Fig. 4A, lined bars). Thus, increasingly malignant cellular trans-
formation renders cells sensitive to CtBP inhibition by MTOB.
MTOB is well tolerated and effective in vivo. To begin to 
address MTOB’s potential clinical utility in cancer therapy, 
MTOB was first assessed for any toxicity in the mouse. Nu/Nu 
mice (3 in each group) received either PBS or 750 mg/kg MTOB 
administered by intraperitoneal (IP) injection twice a week for 
four weeks and all mice were then sacrificed for necropsy. The 
mice showed no signs of illness or distress at the time of sac-
rifice. Tissues from the major organs from one of each group 
were read in a blinded fashion by an outside pathologist and all 
major organs from the MTOB-treated mouse looked no different 
MTOB sensitivity correlates with the degree of cellular 
transformation. To investigate MTOB’s potential cytotoxic 
specificity for malignant cells, MTOB cytotoxicity was assessed 
in primary mouse embryonic fibroblasts (MEFs) with different 
genetic backgrounds. Treatment of primary MEFs with 4 or 10 
mM MTOB for 48 hours revealed no differences in viability 
between treated and control cells (Suppl. Fig. 3A). In a 7-day 
colony assay, primary MEFs likewise showed no difference in 
survival between 4 mM MTOB-treated and untreated samples, 
confirming the lack of toxicity in the shorter experiment (Fig. 
4A, white bars). Immortalized MEFs from p19Arf-null mice, how-
ever, showed greater sensitivity to MTOB, with a 65% reduc-
tion in survival in the 7-day assay (Fig. 4A and black bars). 
Transformation of p19Arf-/- MEFs with c-Myc and activated Ras 
Figure 3. MtoB-induced cell death is dependent on inhibition of CtBp-mediated repression of Bik. (A) HCt116-/- cells were transfected with CtBp2-V5 
or empty pCDNA3 vector, and transfected cells were enriched by G418 selection for one week to form pooled cell lines. once selected, cells were 
plated and treated for 72 hours with either 4 mM MtoB or normal media (control). Cell viability was then determined by trypan blue assay. experi-
ments were performed in triplicate and error bars indicate the SeM. (B) Cell lysates were immunoblotted to detect expression of CtBp2, CtBp2-V5 and 
Bik in the presence (+) and absence (-) of 4 mM MtoB. (C) HCt116-/- cells stably expressing one of two shRNAs targeting Bik or GFp under the control 
of the tet-repressor were plated in the presence of doxycycline for 24 hours before being treated with normal media or 4 mM MtoB. After 72 hours, 
cells were harvested and cell viability determined by trypan blue assay. error bars represent the SeM. (D) Cell lysates were immunoblotted to detect 
expression of Bik in the presence of shGFp or one of two hairpins targeting Bik, shBik1 and shBik2. Bik levels were quantified by densitometry, and 
normalized for GApDH.
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In order to determine MTOB’s efficacy in vivo, a peritoneal 
xenograft model employing HCT116-/- cells was employed. Seven 
days after Nu/Nu mice received 3 x 106 HCT116-/- by IP injec-
tion, mice were randomized into control or treatment groups (10 
each group) and IP injections with PBS or 750 mg/kg MTOB 
histologically than those from the PBS treated mouse (data not 
shown). This data, combined with previous studies of MTOB 
toxicity in animal and human nutrition,30-33 supported the con-
clusion that MTOB has limited or no toxicity in normal cells and 
tissues in vitro and in vivo.
Figure 4. For figure legend, see page 3746.
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A drawback to the peritoneal xenograft model is that tumor 
mass cannot be accurately measured over time prior to necropsy. 
In order to look at the effect of MTOB on tumor size over time, 
overall survival vs. tumor weight were plotted for PBS- and 
MTOB-treated mice (Fig. 4E). The two groups were fit by linear 
regression (PBS slope = 0.26, MTOB slope = -0.008) and the 
slopes’ variance from zero determined by an F-test of the model, 
with the PBS slope being significantly non-zero (p = 0.001), while 
the MTOB slope was not different from zero (p = 0.6). The two 
lines were then compared to each other using analysis of co-vari-
ance (ANCOVA), and they did vary from one another signifi-
cantly, with p = 0.0009. Hence, PBS-treated mice grew tumors 
linearly proportional to their survival, while MTOB-treated mice 
showed no increase in tumor size over the time of the experiment. 
Taken together, these data suggest that MTOB is a potentially 
effective cancer therapeutic molecule and CtBP is a valid target 
for further therapeutic development.
CtBP and ARF levels vary coordinately in human colon 
tumors. CtBP repressors represent potentially attractive cancer 
drug targets, but are only useful as such if expressed in human 
tumors. Recent studies have found increased levels of CtBP1 pro-
tein in adenomas from FAP patients.24,25 CtBP is regulated at the 
post-translational level by several tumors suppressors,19,23,24 but 
there has been no systematic examination of CtBP1 and CtBP2 
protein expression in human tumors. Since the cellular CtBP 
antagonist and tumor suppressor ARF is silenced due to meth-
ylation in ~22–38% of colon cancers,34 a series of 69 resected 
colon cancer specimens were analyzed for tumor-specific CtBP 
expression levels, to probe whether CtBP overexpression occurs 
in human tumors and especially in those tumors lacking ARF. 
Tumor specimens and corresponding adjacent normal tissue were 
thus analyzed for CtBP1/2, hARF and GAPDH protein levels by 
immunoblot (Fig. 5A) and CtBP2 and GAPDH mRNA levels by 
RT-PCR (Fig. 5B).
Three CtBP and ARF expression patterns were observed (Fig. 
5A; Class I–III; summarized in Fig. 5C). The majority of tumors 
(44/69, 64%) expressed substantially higher levels of CtBP1/2 
than adjacent normal tissue and ARF was undetectable in 38/44 
of these class I samples (86%; a faint background band is seen 
migrating just below the ARF position in many samples; rep-
resentative cases in Fig. 5A, #1–3). 17 of the 69 (25%) tumors 
demonstrated a striking absence of CtBP1/2 and most of these 
(14/17, 82%) exhibited expression of p14ARF (class II, represen-
tative cases in Fig. 5A, #4–6). Notably, the matched normal 
were begun three times a week for up to 8 weeks or until sacri-
fice due to tumor progression. Mice were assessed for tumor-free 
survival, tumor weight and production of ascites (Fig. 4). Mice 
treated with MTOB showed a median tumor-free survival of 38 
days compared to 35 days for PBS-treated mice, with a log rank 
test p-value of 0.08 (Fig. 4B). However, 48% of MTOB-treated 
mice were still tumor-free after all PBS-treated mice had visible 
tumor and 16% of the MTOB mice had no tumor at the end of the 
study, suggesting that from the standpoint of tumor-free survival, 
additional statistical power will be needed to establish whether a 
significant p-value can be achieved for this particular endpoint.
Tumor burden was determined by total tumor weight and 
total ascites volume at the time of sacrifice for tumor progres-
sion or study end and a representative portion of tumor from 
each mouse was fixed and stained with hematoxylin and eosin 
(H&E; Fig. 4C and Suppl. Fig. 3B). H&E staining of tumor 
xenografts revealed poorly differentiated adenocarcinoma, with 
normal tissue (stomach, intestine, peritoneum) sometimes cap-
tured on the periphery (Suppl. Fig. 2B). All tumors had vary-
ing degrees of central necrosis and lymphocytic infiltrate. Tumor 
masses accumulated on the viscera and peritoneal surfaces with 
no apparent invasion of other organs. PBS-treated animals had 
tumors weighing an average of 4.7 grams, while MTOB-treated 
tumors were significantly smaller, weighing an average of 1.2 
grams (p = 0.0007) (Fig. 4C, left). Any ascites was aspirated prior 
to necropsy. Only one MTOB-treated animal developed ascites, 
while all but two of the PBS-treated mice did develop ascites. 
The average volume of ascites removed from PBS-treated mice 
was 5.7 mL, while an average of 1.25 mL was removed from the 
MTOB-treated mice and this was mainly attributed to just a sin-
gle mouse (p = 0.04 for difference in ascites volume between PBS 
and MTOB treatments; Fig. 4C, right). Two measures of disease 
burden therefore showed significant improvement with MTOB 
treatment, suggesting that MTOB can effectively reduce tumor 
burden in the HCT116-/- peritoneal xenograft model.
To assess MTOB-induced apoptosis in the tumors, TUNEL 
staining was performed and quantified on seven PBS- and seven 
MTOB-treated tumors, with a significant 11-fold increase in % 
TUNEL-positive cells in MTOB-treated tumors (p = 0.002 by 
Mann Whitney/Wilcoxon rank sum test) (Fig. 4D). The range 
of apoptotic response to MTOB was variable, ranging from a 4 to 
27-fold increase in % TUNEL-positive cells (Fig. 4D, top) and 
this might possibly explain the range of tumor weights observed 
in MTOB-treated mice (Fig. 4E).
Figure 4 (See previous page). MtoB effectively and safely targets cancer cells in vivo. (A) primary wild-type mouse embryonic fibroblasts (MeFs), 
immortalized ARF-/- MeFs, and ARF-/- MeFs stably transfected with mutant Ras and c-Myc vectors were treated for 3 days with 4 mM MtoB or normal 
media (control), followed by four days in normal media. Cell survival of MeF colonies was determined by A595 of solubilized Giemsa-stained cells  
expressed relative to the untreated cells. experiments were performed 3 times in duplicate, and error bars represent the SeM. (B) tumor-free survival 
(tFS) of Nu/Nu mice inoculated with HCt116-/- cells and treated one week later with pBS or 750 mg/kg MtoB three times a week for 7 weeks, unless 
mice were euthanized sooner due to progressive tumor growth. p = 0.08 for comparison of median tFS between pBS and MtoB treatment. (C) tumor 
burden was assessed by measuring total peritoneal tumor weight at time of death or sacrifice (left), and by measuring the volume of ascites before 
necropsy (right). treatment groups were compared by unpaired t-test with tumor weight and ascites both significantly less in the MtoB group  
(p = 0.007 and 0.04, respectively). error bars indicate SeM. (D) Sections of paraffin-embedded tumor were analyzed for apoptosis by tUNeL staining. 
5 high power fields were counted for 7 tumors each from pBS- or MtoB-treated animals, and the averages plotted (top). Differences between the two 
groups were analyzed for statistical significance by Mann-Whitney test, with p = 0.0001. A representative section of pBS and MtoB treated tumors are 
shown at 400x magnification. (e) tumor weights for MtoB- and pBS-treated tumors were plotted against days of survival, analyzed by linear regres-
sion, and the slopes compared by ANCoVA, with a p value of 0.0009.
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normal and tumor specimens across all classes (Fig. 5B), sug-
gesting that the loss of CtBP expression in Class II tumors and 
the increase in CtBP expression in Class I tumors was post-tran-
scriptional. Taken together, the analysis of a series of colorectal 
cancer resection specimens demonstrated an inverse relationship 
between ARF and CtBP protein expression in ~75% of tumors, 
which is consistent with previous results from cell line-based 
studies.19 Additionally a majority (64%) of colon tumors exhib-
ited levels of CtBP expression greater than that seen in normal 
tissue, suggesting that a CtBP inhibitor, such as MTOB, could be 
of utility in colon cancer therapy and of most utility and specific-
ity in class I colon tumors.
Discussion
CtBP is one of only a very few transcription factors that harbor 
an intrinsic enzymatic, and thus druggable, functional domain. 
CtBP is a potential therapeutic target in cancer, therefore, due 
to its numerous pro-oncogenic properties.7,16,17,19 Here we have 
samples for Class II tumors invariably contained detectable and 
comparatively high levels of CtBP1/2 protein, as also seen in 
matched normal samples from Class III tissues (where CtBP lev-
els were the same in normal and tumor tissue; Fig. 5A, #7–9), 
but unlike the matched normal class I specimens (Fig. 5A, #1–3). 
ARF was detected in 3/8 class III samples, but at much lower 
levels of expression compared to class II tumors and variably in 
tumor or normal tissue (e.g., filled circles, #7 and 8, Fig. 5A). 
The inverse correlation between ARF and CtBP was statistically 
significant for comparison of the ARF/CtBP expression pattern 
between samples in Class I vs. II (p = 0.0001), but only trended 
to significance for comparisons of class I or class II samples vs. 
class III samples (Class II vs. III p = 0.06, and Class I vs. III 
p = 0.12) likely because of the smaller numbers of samples in 
classes II and III. Examining the inverse correlation of ARF and 
CtBP expression across all tumor samples revealed a highly signif-
icant chi square value of 26.7 (2 degrees of freedom, p < 0.00001).
RT-PCR analysis of normal and tumor samples for CtBP2 
mRNA showed no consistent or significant difference between 
Figure 5. CtBp and p14ARF levels are inversely-correlated in human colorectal adenocarcinomas. (A) Samples from colorectal adenocarcinoma speci-
mens were analyzed by immunoblot for levels of p14ARF, CtBp1/2 and GApDH. tumors were separated into three groups based on the CtBp levels in 
tumor vs. normal tissue. Representative blots from the three groups are shown. (B) RNA was isolated from the same tumors and Rt-pCR performed to 
determine CtBp2 and GApDH mRNA levels in tumor vs. normal tissue. (C) Summary of the three classes of colorectal tumors based on CtBp and ARF 
expression levels. the inverse correlation of ARF and CtBp1/2 expression was significant by exact Fischer’s test with p = 0.0001 for Class I vs. Class II,  
p = 0.06 for Class II vs. Class III, but not siginificant for the comparison of Class I vs. Class III (p = 0.12).
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of grams/day, with chicks showing no toxicity after receiving 
15 g/kg daily,32 suggesting the compound is well tolerated by 
healthy tissues in animals, as well as humans.
As to why MTOB is selectively more toxic to transformed 
cells is not yet clear. CtBP1/2 hetero- and homozygous knock-
out MEFs grow normally, but are hypersensitive to apoptotic 
stress.8,45 The constitutive apoptogenic stresses found in malig-
nant cells46 might cause them to rely on enhanced or constitutive 
CtBP activity, whereas non-transformed cells are not under con-
stant stress, and thus may be less dependent on CtBP activity for 
survival. It is therefore unclear whether improvement in MTOB’s 
inhibition of CtBP with a more potent chemical inhibitor would 
improve or reduce the therapeutic window of CtBP inhibition.
The evidence for a role of CtBP in human cancer is grow-
ing. CtBP has been shown to regulate processes important for 
oncogenesis, tumor maintenance, and progression/metastasis.16 
We have demonstrated that the CtBP substrate and methionine 
salvage intermediate, MTOB, preferentially kills cancer cells. We 
have identified CtBP, and its repression of Bik, as the putative 
target responsible for MTOB-induced cell death. MTOB can be 
successfully, and safely, delivered to tumor cells in vivo. These 
findings suggest that the dehydrogenase activity of CtBP proteins 
may represent a viable drug target, and further detailed investi-
gation of the mechanism of CtBP inhibition by MTOB and its 
clinical usefulness is warranted.
Materials and Methods
Plasmids and viral expression vectors. V5-tagged CtBP2 expres-
sion plasmid pcDNA-V5-CtBP2 has been described.19 c-Myc and 
RasV12 expression plasmids were generously provided by Dr. 
Ron DePinho.
Chemicals. 4-methylthio-2-oxobutyric Acid (Sigma) was dis-
solved in cell-specific media, 0.2 um filtered, and diluted to final 
concentration before addition to cultured cells.
Cell culture and transfection. HCT116 human colon cancer 
cells (ARF silenced) with (-/-) and without (+/+) targeted dele-
tion of p53,47 were grown in McCoy’s 5A medium with 10% fetal 
bovine serum and 100 U/ml penicillin, 100 μg/ml of streptomy-
cin. MEFs were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum, 100 U/ml 
penicillin, 100 μg/ml of streptomycin, and incubated in humidi-
fied 5% CO
2
 at 37°C. MCF7 human breast carcinoma cells were 
grown in the same medium, with glucose levels reduced to 1 g/L. 
MCF10A human breast adenoma cells were grown in DMEM 
F-12 media as described.48 Mammalian expression plasmids were 
transfected using Fugene (Roche). HCT116-/- cells stably express-
ing shRNAs targeting Bik were described previously.26
Immunoblotting. Cells were lysed in lysis buffer (20 mM 
HEPES pH 7.4, 0.5% Triton X-100, 2 mM MgCl
2
, 10 μM 
ZnCl
2
, 2 mM NEM, 1 mM PMSF, 240 mM NaCl) contain-
ing protease inhibitor tablets (Roche).7 Antibodies used were 
as follows: CTBP1, CtBP2 (BD Biosciences), hARF (Novus), 
V-5 (Invitrogen), GAPDH (Advanced Immuno), E-cadherin, 
hBik and cleaved caspase 3 (Cell Signalling). Anti-rabbit 
IgG-horseradish peroxidase and anti-mouse IgG-horseradish 
shown that the CtBP substrate MTOB regulates CtBP activities 
in vivo. Repression of a specific CtBP gene product, Bik, was alle-
viated with MTOB treatment, coinciding with decreased CtBP 
occupancy on the target promoter. CtBP2 rescue of MTOB-
induced cell death was complete, as was rescue by RNAi knock-
down of the BH3-only protein Bik, supporting the hypothesis 
that MTOB-induced cell death is caused by interfering with 
CtBP repression of Bik. Immortalized and transformed MEFs 
were sensitized to MTOB cytotoxic effects in comparison to nor-
mal MEFs, indicating that MTOB may exhibit its toxic effects 
specifically in cancer cells. In vivo testing of MTOB in colon 
cancer peritoneal xenografts demonstrated it to be a safe, well-
tolerated therapy, with an ability to limit tumor growth and asci-
tes production and possibly prolong survival.
In an effort to validate the usefulness of CtBP as a therapeutic 
target in human cancer, we have shown that CtBP1/2 protein is 
overexpressed relative to normal tissue in 64% of resected colorec-
tal tumors, likely due to concomitant ARF loss and increased 
CtBP protein stability. Only a minority of tumors (25%) exhib-
ited low CtBP levels, and in this group of tumors ARF and CtBP 
expression were inversely correlated in ~80% of specimens. Thus, 
abnormally high levels of CtBP were associated with greater than 
50% of colon adenocarcinoma specimens, suggesting that a sub-
stantial fraction of colon cancers may exhibit heightened sensitiv-
ity to anti-CtBP therapy.
Bik has been implicated as a human tumor suppressor, with 
epigenetic silencing, deletions or mutations detected in renal, 
colon, brain, and lymphatic malignancies.35-38 Bik upregulation 
is linked to apoptosis induced by a variety of anti-neoplastic 
agents, such as cisplatin, doxorubicin, 5'-aza-2'deoxycytidine 
(DNA methyltransferase 1 inhibitor), and the proteasome inhibi-
tor bortezomib.39 Bik overexpression has been reported to reduce 
chemotherapy resistance in vitro,40 as well as dramatically reduce 
tumor formation in mouse models in vivo.41,42 Thus, molecules 
that can induce Bik expression, such as MTOB or another CtBP 
inhibitor, could be useful in the treatment of a wide spectrum of 
malignancies.
In addition to upregulating pro-apoptotic gene targets, CtBP 
inhibition could have additional therapeutic value. CtBP was 
recently identified as a transcriptional activator of the multi-drug 
resistance transporter (MDR1; Pg-p).43 In a chemoresistant cell 
line, sensitivity was reestablished with RNAi depletion of CtBP, 
corresponding with reduced CtBP binding of the MDR1 pro-
moter. MTOB induction of chemotherapy sensitivity to other 
therapeutics, outside of its intrinsic induction apoptosis, may be 
clinically useful as well.
The evidence to date suggests that MTOB or other compounds 
that target CtBP are viable candidates for therapeutic develop-
ment. MTOB is toxic to a variety of cancer cell lines derived 
from many different tissues (reviewed in ref. 29). In our study, 
MTOB toxicity was relatively specific for transformed cells, with 
early passage mouse embryonic fibroblasts showing near com-
plete resistance to the compound. MTOB has been evaluated as a 
methionine supplement in livestock feed,32 as well as used in the 
treatment of uremic patients, without reported toxicity.30,31,44 The 
oral doses used in both humans and animals were on the order 
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AAG CTG GCC ACA GCT C-3'/antisense 5'-CCA TCA TGT 
TGG CCA GAA TGG TCT C-3'.
Tumor sample analysis. Whole cell lysates (for protein analy-
sis) and total RNA from tumor and associated normal samples 
(colon adenocarcinoma resection specimens, UMass Memorial 
Cancer Center Tumor Bank, anonymous deidentified samples 
with stages I–IV represented) were prepared using a PARIS® kit 
(Ambion). RT-PCR was performed using the Stratascript® RT kit 
(Stratagene) using primers for CtBP2 and GAPDH as described.26
MTOB treatment of peritoneal xenograft tumors. Mouse tox-
icity and xenograft studies were approved by the UMass Medical 
School Institutional Animal Care and Use Committee. For the 
toxicity study, male Nu/Nu mice (Charles River Laboratories; 
3 reach group) were injected IP with PBS or 750 mg/kg MTOB 
prepared in PBS twice weekly for 4 weeks, and then sacrificed 
for necropsy and histopathological analysis of all major organs. 
Slides were read in a blinded fashion by D. Garlick, UMass 
Memorial Cancer Center Veterinary Pathology Core. Male Nu/
Nu mice were then inoculated with 3 x 106 HCT116-/- cells in 
PBS by intraperitoneal injection. One week after inoculation, 
mice were randomized into 2 groups (n = 10 mice/treatment 
group) and injected three times a week (M,W,F) with either PBS 
or 750 mg/kg MTOB prepared in PBS. Mice were necropsied 
at time of death or sacrificed when determined by a third party 
to be moribund or too burdened by ascites. Tumor-free survival 
was plotted as a Kaplan-Meier curve using Prism Graphpad soft-
ware (GraphPad Software). Any ascites was aspirated before nec-
ropsy and volume quantitated in ml. Total peritoneal tumor mass 
was measured by weight in grams. Tumor weight and ascites in 
MTOB- vs. PBS-treated mice were analyzed by unpaired student 
t-test. Tumor weight as a function of survival time was analyzed 
by an F-test of both linear regression models and an analysis of 
covariance (ANCOVA), to determine the difference between the 
PBS and MTOB-treated groups.
TUNEL staining. After weighing, peritoneal xenograft 
tumors were fixed in formalin. Paraffin-embedded tumor sec-
tions were analyzed for apoptosis using a peroxidase based In 
Situ Cell Death Detection Kit (Roche). The staining was auto-
mated using the Discovery XT (Ventana Medical Systems). 
TUNEL-positive cells from 5 fields from each slide, excluding 
necrotic fields, were counted. The Mann-Whitney/Wilcoxon 
rank-sum test was used to determine statistical significance in 
fold change of % TUNEL-positive cells using Prism Graphpad 
software. Images were taken using an Olympus BX41 microscope 
(Olympus) with 200x or 400x magnification. The images were 
acquired with an Evolution MP 5.0 camera (Media Cybernetics) 
and Q Capture Pro 5.1 (QImaging) image acquisition 
software.
Real-time quantitative PCR. mRNA transcripts for human 
Bik and GAPDH were analyzed by RQ-PCR using SYBR green 
(Applied Biosystems) on an ABI 7300 (Applied Biosystems). 
Relative amounts of the mRNA transcripts were calculated using 
the ΔΔCT method with GAPDH mRNA as the internal refer-
ence. The primer sets used were Bik (sense: 5'-TCC TAT GGC 
TCT GCA ATT GTC A-3'/antisense: 5'-GGC AGG AGT GAA 
TGG CTC TTC-3'); GAPDH (sense 5'-ATC ACC ATC TTC 
peroxidase conjugates (Jackson Immunoresearch) were detected 
on immunoblots by ECL (GE Healthcare).
Cell viability, colony and relative survival assays. For viabil-
ity determination, cells were analyzed by trypan blue staining 
or MTT assay. For trypan blue studies, cells were trypsinized, 
washed and mixed 1:1 with trypan blue solution and counted 
with a hemocytometer. For MTT assays, cells were combined 
with MTT reagent (Calbiochem) according to manufacturers 
instructions, and developed for one hour before determination 
of A
595
.
Colony assays were performed in duplicate in six-well plates. 
Cells were plated at a limiting dilution and treated for 72 hours 
with no additive or MTOB-containing media. After 72 hours, 
media was replaced with fresh media without MTOB every two 
days, until fixation with methanol and acetic acid. After fixation, 
colonies were stained with Giemsa, and then either counted or 
resolubilized in methanol and SDS followed by determination of 
A
595
 as described.49
Chromatin immunoprecipitation assay (ChIP). 108 cells per 
ChIP assay were washed once in PBS and treated with 1% form-
aldehyde in cold PBS for 10 min at 4°C with continuous shaking. 
Glycine (final concentration 125 mM) was added to quench the 
formaldehyde for 5 min at 4°C with continuous shaking. Cells 
were then harvested and washed twice with ice-cold PBS. Nuclei 
were isolated by incubating the cells in nucleus isolation buffer 
(5 mM PIPES pH 8.0, 85 mM KCl, and 0.5% NP-40) for 20 to 
30 min on ice. The nuclei were harvested at 4°C by centrifuging 
the cell suspension at 7,000x g for 5 min, and resuspended in 2 
ml of RIPA buffer (150 mM NaCl, 1% v/v NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0, 5 mM ethylenedi-
amine tetra-acetic acid (EDTA)) containing protease inhibitors. 
Chromatin was fragmented to approximately 200–700 bp by son-
ication. Nuclear debris was removed by centrifuging the lysates at 
4°C for 15 min at 14,000 rpm. The lysate was precleared by incu-
bation with protein G Sepharose beads for 30 min at 4°C and 
immunoprecipitation was performed overnight at 4°C with the 
respective antibody. Protein G Sepharose beads were added and 
the immunocomplexes were allowed to bind to the beads for 2 
hours at 4°C. The beads were then washed once each with RIPA 
buffer, RIPA buffer with 500 mM NaCl, immunoprecipitation 
wash buffer (10 mM Tris pH 8.0, 250 mM LiCl, 0.5% NP40, 
0.5% sodium deoxycholate, 1 mM EDTA), and finally with TE 
(10 mM Tris pH 8.0, 1 mM EDTA). Beads were resuspended in 
200 μl of elution buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 
1% SDS) with Proteinase K (20 mg/ml) and incubated overnight 
at 55oC. DNA was extracted using phenol-chloroform, precipi-
tated in the presence of glycogen by ethanol, allowed to air-dry, 
and dissolved in TE. Immunoprecipitated DNA was diluted 
10-fold prior to PCR. The following primer sets were used to 
amplify different regions of the genes indicated: Bik promoter 
primer set (fragment endpoints -551 bp to -693 bp relative to Bik 
transcription start site) in which tandem BKLF-binding sites are 
present; sense 5'-TAT ACC AGG GCT GGA GTT AGG TCC-
3'/antisense 5'-CTC ACG TGC AGA CCT GGT GAG A-3'; 
non-specific primers (NS) (fragment endpoints -9.5 to -9.3 kb 
relative to the Bik transcription start site) sense 5'-CCT AAG 
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